Two animations explaining the Mechanism of Action (MOA) of ACU193, a monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers for the treatment of early Alzheimer’s disease.
The top animation has been created with the objective of informing potential study participants about the MOA of ACU193 in a clear and simple way. It is being used to help enroll patients into a clinical trial.
The bottom animation includes more scientific concepts and is intended to be used for investor presentations.
Copyright © 2022, Acumen Pharmaceuticals, Inc.
Client: Acumen Pharmaceuticals, Inc., (Charlottesville, VA, USA).